Atomoxetine and Huntington's Disease

• Status: Completed
• Trial end date: 2008-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research study is to evaluate the effect of atomoxetine (also known as Strattera) compared to placebo (inactive substance) on daily activities such as attention and focus, thinking ability and muscle movements in subjects with early Huntington Disease (HD) and attention deficit disorder (ADD).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Iowa
• Collaborator: Eli Lilly and Company
• Treatments: Atomoxetine Hydrochloride

Criteria

Inclusion Criteria:

• Confirmed Huntington's disease (HD) diagnosis

• Age 18 to 65

• Must have mild HD

• Must have complaints of poor attention

Exclusion Criteria:

• Childhood history of attention deficit hyperactivity disorder (ADHD) symptoms

• Diagnosis of schizophrenia, bipolar affective disorder, dementia, delirium or severe anxiety

• Current use of a monoamine oxidase inhibitor (MAOI) medication

• Pregnancy

• Uncontrolled hypertension

• Tachycardia

• Cardiovascular or cerebrovascular disease

• History of a loss of consciousness for greater than (or equal to) 5 minutes

• Having any neurological disorder or insult other than Huntington disease